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Abstract
Background: Mutations in genes encoding desmosomal proteins have been reported to cause
arrhythmogenic right ventricular cardiomyopathy (ARVC), an autosomal dominant disease
characterised by progressive myocardial atrophy with fibro-fatty replacement.
We screened 54 ARVC probands for mutations in desmocollin-2 (DSC2), the only desmocollin
isoform expressed in cardiac tissue.
Methods:  Mutation screening was performed by denaturing high-performance liquid
chromatography and direct sequencing.
To evaluate the pathogenic potentials of the DSC2 mutations detected in patients affected with
ARVC, full-length wild-type and mutated cDNAs were cloned in eukaryotic expression vectors to
obtain a fusion protein with green fluorescence protein (GFP); constructs were transfected in
neonatal rat cardiomyocytes and in HL-1 cells.
Results:  We identified two heterozygous mutations (c.304G>A (p.E102K) and c.1034T>C
(p.I345T)) in two probands and in four family members. The two mutations p.E102K and p.I345T
map to the N-terminal region, relevant to adhesive interactions.
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In vitro functional studies demonstrated that, unlike wild-type DSC2, the two N-terminal mutants
are predominantly localised in the cytoplasm.
Conclusion: The two missense mutations in the N-terminal domain affect the normal localisation
of DSC2, thus suggesting the potential pathogenic effect of the reported mutations. Identification
of additional DSC2 mutations associated with ARVC may result in increased diagnostic accuracy
with implications for genetic counseling.
Background
Arrhythmogenic right ventricular cardiomyopathy
(ARVC) (MIM #107970) is a myocardial disease in which
myocardium of the right ventricular free wall is partially
or almost entirely replaced by fibro-fatty tissue [1], lead-
ing to structural and functional abnormalities of the right
ventricle, electrocardiographic depolarization/repolariza-
tion changes and arrhythmias of right ventricular origin
[2]. Clinical symptoms are manifested in the early adult-
hood.
The disease is transmitted as an autosomal dominant trait
with reduced penetrance. Although pathogenic mutations
underlying ARVC were detected in RyR2 (cardiac ryanod-
ine receptor) [3] and in TGFβ3 (transforming growth fac-
tor-β3) [4] genes, finding mutations in genes encoding
desmosomal proteins, namely Desmoplakin (DSP), Pla-
kophilin-2 (PKP2) and Desmoglein-2 (DSG2) [5-7] led to
current idea that ARVC is due to desmosomal dysfunction
[8]. This was further strengthened by two recent studies
that reported mutations in the desmosomal desmocollin-
2 (DSC2) gene as the cause of ARVC [9,10]. Actually, also
the autosomal recessive form of ARVC, known as Naxos
syndrome, associated with palmoplantar keratoderma
and peculiar woolly hairs (MIM #601214) is due to muta-
tion in the desmosomal protein Plakoglobin (JUP) [11].
Moreover, intercalated discs ultrastructural abnormalities
consisting of decreased desmosome number and intercel-
lular gap widening were observed in ARVC biopsy sam-
ples [12].
Desmosomes anchor stress-bearing intermediate fila-
ments at sites of strong intercellular adhesion; the result-
ing scaffold plays a key role in providing mechanical
integrity of tissues which undergo high mechanical stress,
such as epidermis and heart [13]. Desmosomes include
proteins from at least three distinct gene families: cadher-
ins, armadillo proteins and plakins [14]. Desmosomal
cadherins include DSGs and DSCs; members of both sub-
families are single-pass transmembrane glycoproteins,
mediating Ca2+-dependent cell-cell adhesion.
We report here two novel mutations of the DSC2 gene
detected in patients affected with ARVC and their func-
tional characterization.
Methods
Clinical evaluation
Clinical diagnosis of ARVC was based on major and
minor criteria established by the European Society of Car-
diology/International Society and Federation of Cardiol-
ogy Task Force [15]. The study involved a cohort of 54
patients of Italian descent. Each patient underwent cardi-
ological examination. The clinical study protocol
included 12-lead electrocardiogram (ECG), signal-aver-
aged ECG (SAECG), 24-hour Holter ECG, and 2-dimen-
sional echocardiography, performed according to
previously reported methods [2]. All clinical investiga-
tions and blood sampling for DNA analysis were per-
formed under informed consent, according to the
pertinent Italian legislation and in compliance with Hel-
sinki declaration.
Mutation screening
Fifty-four Italian probands (33 males and 21 females),
which proved negative for mutations of DSP, PKP2, DSG2
and TGFβ3 genes, were screened for DSC2 mutations by
denaturing high-performance liquid chromatography
(DHPLC) and direct sequencing.
Primers flanking each exon of the human DSC2 gene were
designed by PRIMER3. PCR amplifications were per-
formed in a final volume of 25 µl, containing 50 ng of
genomic DNA, 400 nmol/l of each primer (Sigma Geno-
sys), 100 µmol/l of each dNTP, 1.5 µmol/l MgCl2, and 0.8
U of Taq DNA Polymerase (TaqGold, Applied Biosys-
tems). PCR primers and DHPLC conditions are reported
in Table 1. DHPLC analysis was performed with the use of
WAVE Nucleic Acid Fragment Analysis System 3500 HT
(Transgenomic Ltd NE, USA). Samples showing a change
in DHPLC pattern were directly sequenced. DSC2
sequences were compared to reference sequence
NM_024422.
A control group of 250 healthy and unrelated subjects
(500 chromosomes) from Italian population was used for
assessing possible polymorphism of detected DNA vari-
ants. All controls were matched to the probands by ances-
try.
Presence of the missense mutations p.E102K and p.I345T
was confirmed by restriction digest of PCR ampliconsBMC Medical Genetics 2007, 8:65 http://www.biomedcentral.com/1471-2350/8/65
Page 3 of 10
(page number not for citation purposes)
with  TspR1  restriction enzyme (NEW ENGLAND
BioLabs).
Cell cultures
Cardiac ventricular myocytes from one to three days old
Crl:(WI)BR-Wistar rats (Charles River Laboratories, Wilm-
ington, MA) were prepared as previously described [16].
All animal procedures were followed according to institu-
tional guidelines.
HL-1 cardiac myocytes were maintained as previously
reported [17].
Plasmid construction
The cDNA of human DSC2a was kindly provided by Dr
W.W. Franke (Heidelberg, Germany) and human DSC2a
full-length coding sequence (GenBank NM_024422) was
PCR-amplified with the following primers: DSC2a-clonF:
ATTATGGAGGCAGCCCGCCC;  DSC2a-clonR: GTCTCT-
TCATGCATGCTTCTGCTAG. The resulting fragment was
cloned into pcDNA3.1/CT-GFP-topo eukaryotic expres-
sion vector (Invitrogen) which contains cDNA coding for
green fluorescent protein (GFP), and verified by sequence
analysis.
Site directed mutagenesis
Site-directed mutagenesis was performed on DSC2a-
pcDNA3.1/CT-GFP, in order to reproduce two DSC2 nat-
urally occurring mutations: p.E102K (EF017811), and
p.I345T (EF017812). We used the QuikChange XL Site-
Directed Mutagenesis Kit (Stratagene) and the following
mutagenic primers: E102K-F: TACCATATTACTTTC-
CAACACTAAGAACCAAGAAAAGAAGAAAAT; E102K-R:
ATTTTCTTCTTTTCTTGGTTCTTAGTGTTGGAAAG-
TAATATGGTA; I345T-F: CAACTTCAACTTGTATCATTAAC
ACTGATGATGTAAATGACCACTTGC; I345T-R: GC
AAGTGGTCATTTACATCATCAGTGTTAATGATACAAGTT-
GAAGTTG. All clones were verified by sequence analysis.
Transfection of neonatal rat cardiomyocytes and HL-1 
cells with wild-type and mutant DSC2a-pcDNA3.1/CT
After 1 day in culture, cardiomyocytes were transfected
with 3 µg of plasmid DNA per well and 8 µl of transfection
reagent (transfectin lipid reagent Biorad). After 24 hours
of transfection, cells were fixed for 20 minutes with 4%
paraformaldehyde in phosphate-buffered saline, and then
permeabilized with 0.1% Triton X-100 for 10 minutes.
HL-1 cells were transfected with 0.8 µg of plasmid DNA
per plate, 6.4 µl of enhancer reagent, and 8 µl of effectene
reagent (Qiagen). At 48 hours post-transfection, HL-1
cells were fixed with cold methanol/acetone (1:1) for 20
minutes at -20°C. Each set of subsequent experiments was
performed in triplicate in 24 mm glass coverslips and was
repeated 3 times.
Immunostaining and confocal imaging on neonatal rat 
cardiomyocytes and HL-1 cells
Neonatal rat cardiomyocytes were stained with anti-alpha
actinin antibody (Sigma) for two hours at room tempera-
ture, washed three times with PBS and incubated with
Alexa fluor 543-conjugated antimouse antibody (Molecu-
lar Probes, Eugene, Ore). HL-1 cells were incubated with
the murine mAb (clone DG3.10) against bovine dsg
(PROGEN, Heidelberg, Germany), which reacts with a
carboxy terminal epitope of desmoglein for 30 min at
Table 1: PCR primers and conditions for DHPLC analysis of DSC2 gene
EXON bp T°C DHPLC Forward 5' 3' Reverse 5' 3'
1+5'UTR 708 Direct sequencing TCAGACCTCGCTCTGTAATTGA TATCCCCGTTCCCCTAGTTT
2 199 Direct sequencing ACACATTAAAGTTTTCTTTTTAT GGCGTATATGTACCACAGCA
3 400 54,8/55,4 CCCCACGTGCATACATTACT TGGTTTTCATTCGTCTTTAAGC
4 269 55,6/58.5 CCCCTACCCAGCTAATCCTC GGAAACTATAGACTCCCACAGCA
5 332 56,5/57,2 TGAAAGCTCTGCTGAAATAAAGA GGAGTAGCCAGAGCATTGGT
6 266 54.7 GCCAAAATGAATTTGAAGCATAC TTGAAACACAGTTAATTTGCCATA
7 384 55/58/59,5 CATAGAACATGTGAATGTTTTGGA CAAAACCAGCATACTCCAAGG
8 252 54,3/55.6 GTTGGTGCTTTCCCCCAATA AGGCCAGAGATGTGCATATTA
9 324 52.2/53.5/55.3 CATCGTGTTCAATTTTTGTGA CCTTTCTTTCCATTAAATTCTAGC
10 374 56,5/57,9 ACTCGTTAGCATTGCCAAAT TAACGTAACAAAATAAGCTA
11 375 51,7/56 CAAGAAGTAGCAGTGGCATAAGG AACAGAGTGCATGTATCCAGCTT
12 345 57/58/59 GTGTTCAGTGCATACTTTTGTGG GCAGACATCCTGATGTTGAAAA
13 356 57,2/58 TGTTCAGAAGAAATCAGTGACA GTGTCTTGAAAGTTACTTTAAAGG
14 263 57.7 GATTTATGTGTGTATTAACCATTG CGCATTATAAGCGAATTCATCC
15 a 194 56.2/60.6/61.8 CATAATTTTGTGTTCCTCTCTGT AGGATTCCGAGGTCTGGTGT
b 332 61/61,4/62,2 GGCTTCACAACCCAAACTGT TGAAAATTATAGTCAGAATCCAGT
15' 226 53,7/55,2 GCCACATGCGTGACTTTTAG ACTTTCTGCCAAGGGGAAAA
16 397 56,3/56,8 CAATGAAAGGTAAATCAAAGCAA AAAAACCCCCACAAATAGCABMC Medical Genetics 2007, 8:65 http://www.biomedcentral.com/1471-2350/8/65
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37°C, washed three times with PBS, and incubated with
TRITC conjugated antibodies (DAKO).
Slides were inspected and photographed using a Radiance
2000 confocal microscope (BioRad) with a 60× oil objec-
tive.
Results
Genetic analysis
Exon-by-exon analysis of coding sequences of DSC2 gene
was performed on genomic DNA of 54 ARVC probands
negative for mutation screening of genes known to be
associated with ARVC. Two heterozygous point substitu-
tions c.304G>A and c.1034T>C were detected in two
patients (Figure 1). None of the detected nucleotide
changes was found in a control group of 250 healthy and
unrelated subjects (500 control chromosomes) from Ital-
ian population. Mutations were confirmed by restriction
digest.
Variations c.304G>A and c.1034T>C result in predicted
p.E102K and p.I345T amino acid substitutions. The
mutated amino acids had completely different physico-
chemical properties when compared to the wild type.
Mutation p.E102K replaced a negatively-charged residue
by a positively-charged one, whereas mutation p.I345T
replaced a non polar hydrophobic amino acid by a polar
hydrophilic amino acid.
a) Evolutionary conservation of the DSC2 missense mutations p.E102K and p.I345T among 7 species Figure 1
a) Evolutionary conservation of the DSC2 missense mutations p.E102K and p.I345T among 7 species: H. sapiens (AAH63291.1), 
C. familiaris (CAA05309.1), predicted B. taurus (XP_615164.2), predicted M. mulatta (XP_001102096.1), predicted P. troglodytes 
(XP_512077.2), M. musculus (AAH57867.1) and R. norvegicus (NP_001028860.1). The mutated amino acids are coloured, and 
the identities across species are indicated by a different background. b) Pedigrees of ARVC probands carrying DSC2 mutations. 
Black, white, and grey symbols represent clinically affected individuals, unaffected individuals, and individuals of unknown dis-
ease status, respectively. SD indicates sudden death. Presence (*) or absence (-) of the DSC2 mutation is indicated. Arrows 
indicate index cases. Sequence electropherograms, on the right side of the pedigrees, show the two DSC2 missense mutations 
(c.304G>A (p.E102K) and c.1034T>C (p.I345T)). Numbering of the nucleotides starts at ATG and refers to GenBank Acces-
sion number NM_024422.BMC Medical Genetics 2007, 8:65 http://www.biomedcentral.com/1471-2350/8/65
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Mutation p.E102K is located in the propeptide domain,
whereas mutation p.I345T is located in the second extra-
cellular cadherin (EC2) domain and altered the third
amino acid of the EC domain consensus sequence [L/I/V-
x-L/I/V-x-D-x-N-D-N/H-x-P] [18]. Cadherin domains are
important for adhesive interactions and form Ca2+
dependent rodlike structures.
Both these changes occurred in a residue highly conserved
among species (Figure 1a), although in mouse and rat
dsc2 protein, E102 is replaced by aspartic acid. However,
these two amino acids show very similar physico-chemi-
cal properties.
Clinical findings
Main clinical findings of patients carrying DSC2 muta-
tions are reported in Table 2.
p.E102K
The proband (II,2, Fam #149) (Figure 1b) was examined
at the age of 19 years due to premature ventricular beats
with left bundle branch block morphology. The ECG
showed the presence of incomplete right bundle branch
block, whereas late potentials were present at 40–80 filter
setting. Two-D echocardiogram demonstrated a dilated
right ventricle with kinetic abnormalities and decreased
ejection fraction. The left ventricle was dilated as well. His
father and the two brothers carrying the same missense
mutation did not fulfilled the current diagnostic criteria
for ARVC.
p.I345T
The proband (II,1, Fam #170) (Figure 1b) was diagnosed
at the age of 50 years, due to a sustained VT episode for
which he received an implantable cardioverter defibrilla-
tor. The 12-lead ECG showed negative T wave in V4–V6,
whereas late potentials were present at 40–80/250 filters.
Two-D echocardiogram demonstrated a right ventricular
enlargement with moderately depressed ejection fraction;
the left ventricle was segmentary involved. The 15 years-
old daughter, who did not show any arrhythmic symp-
tom, was found to carry the same DSC2 mutation. The
2D-echocardiogram revealed mild right ventricular
abnormalities, whereas 12-lead ECG was normal.
All family members not carrying DSC2 mutations were
negative at clinical investigation.
Functional Analysis of N-terminal Mutant Desmocollins
To evaluate the pathogenic potentials of the DSC2 mis-
sense mutations reported in the present study, full-length
wild-type cDNA was directionally cloned in eukaryotic
expression vector to obtain a fusion protein with GFP.
Mutated proteins carrying p.E102K and p.I345T were
obtained by site directed mutagenesis of the wild-type
construct. Constructs were transfected in neonatal rat car-
diomyocytes and in the desmosome-forming cell line HL-
1.
In neonatal rat cardiomyocytes, wild-type fusion protein
was localised at the cell membrane, only at the interface
between two neighbouring cells (Figure 2, panel A). By
contrast, protein carrying the p.E102K mutation was dis-
tributed in dots both in the membrane and in the cyto-
plasm (Figure 2, panel B), whereas protein carrying
p.I345T mutation was predominantly localised in the
cytoplasm (Figure 2, panel C). Moreover, the membrane
localisation of both mutated proteins was not restricted to
cell-cell junctions (see arrows in Figure 2 panel B" and
C").
In transfected HL-1 cells, wild-type fusion protein was
detected in the cell membrane, into cell-cell contact
regions (Figure 2, panel D), and co-localised with the
endogenous dsg, which was marked with monoclonal
desmoglein antibody (Figure 2, panel D' and D"). This co-
localisation suggests that the wild-type fusion protein has
been integrated into normal-appearing desmosomes.
p.E102K and p.I345T mutant fusion proteins showed the
same distribution observed in neonatal rat cardiomyo-
cytes (Figure 2, panel E and F).
In addition, immunostaining with monoclonal desmo-
glein antibody showed both the presence of well-assem-
bled desmosomes in transfected HL-1 cells (Figure 2,
panel E', F') and the reduced co-localisation between
endogenous dsg and mutated DSC2 (Figure 2, panel E",
F").
Discussion
In the present study, we identified two mutations in DSC2
gene associated with ARVC, a genetically determined heart
muscle disease characterized by structural, electrical, and
pathological abnormalities of the right ventricle. Thus far,
only 3 DSC2  mutations have been reported in ARVC
patients [9,10]. On the basis of present data and of those
previously reported [9,10], DSC2 mutations account for
only a small percentage of ARVC probands.
Desmosomal cadherins, DSGs and DSCs, mediate cell-cell
adhesion by interacting laterally and transcellularly with
each other and by recruiting cytoplasmic plaque proteins
which facilitate attachment of intermediate filaments. In
particular, DSCs dimerise laterally via homophilic and
heterophilic interactions at the cell surface and also make
head-to-head contacts across the intercellular gap to form
the so-called "adhesive zipper" [19]. Moreover, it has been
suggested that DSC2 expressed at cell surface might act as
nucleation centres for subsequent assembly of functional
desmosomes [20].B
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Table 2: Clinical and genetic findings in DSC2 mutation carriers
Proband# (Family #) Sex Age at diagnosis/
Last follow-up
Family 
history
12-lead ECG SAECG Arrhythmias RV size/function LV involv Diagnostic 
criteria
Nucleotide 
change
AA change GenBank 
accession 
number
Major Minor Negative T waves 
preocordial leads
Negative T 
waves inferior leads
IncomRBBB Epsilon wave PVCs >
1000/24 h NSVT
LBBB SVT VF Major Minor
I1 (Fam149) M 58 - + - - - - - - - - - - - 1 m c.304G>A p.E102K EF017811
II1 (Fam149) M 22 - + - - + - - - - - - + - 3 m c.304G>A p.E102K EF017811
II2 (Fam149) M 19 - - - - + - + + - - + - + 1 M/3 m c.304G>A p.E102K EF017811
II3 (Fam149) M 25 - + - - - - - - - - - + - 2 m c.304G>A p.E102K EF017811
II1 (Fam170) M 50 - + V4–V6 - - + + - + - + - + 2 M/3 m c.1034T>C p.I345T EF017812
III2 (Fam170) F 15 - + - - - - - - - - - + - 2 m c.1034T>C p.I345T EF017812
LBBB indicates left bundle-branch block; LV, left ventricular; NSVT, nonsustained ventricular tachycardia; RV, right ventricular; SVT, sustained ventricular tachycardia; VF, ventricular fibrillation; and 
M, major diagnostic criteria, m, minor diagnostic criteriaBMC Medical Genetics 2007, 8:65 http://www.biomedcentral.com/1471-2350/8/65
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Transfection studies in cultured neonatal rat cardiomyocytes (top panels) and HL-1 cells (bottom panels) Figure 2
Transfection studies in cultured neonatal rat cardiomyocytes (top panels) and HL-1 cells (bottom panels). Note the WT-
DSC2a-GFP was localised at the cell membrane between two cardiomyocytes and HL-1 cells (panel A and D), whereas E102K 
and I345T-DSC2a-GFP were mainly detected in the cytoplasm (panel B, C, E and F). As a reference, in cardiomyocytes immu-
nostaining of the same cells with a monoclonal anti-alpha-actinin (panel A', B' and C') and overlay of the DSC2a-GFP and alpha-
actinin staining (panel A", B" and C") are shown. In HL-1 cells immunostaining with monoclonal desmoglein antibody DG 3.10 
showed both the presence of well-assembled desmosomes (panel D', E' and F') and the reduced co-localisation between 
endogenous dsg and mutated DSC2 (yellow dots in panel E", F").BMC Medical Genetics 2007, 8:65 http://www.biomedcentral.com/1471-2350/8/65
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Desmocollins bind desmosomal cadherins through their
extracellular domains, while the cytoplasmic domains
have binding sites for desmosomal plaque proteins. DSCs
occur as "a" and "b" splice variants, with the "a" variant
having a slightly longer cytoplasmic domain. It has been
shown that the "a" variant can support desmosomal
assembly [21], but there is no known function for the "b"
form. In humans, there are three desmocollin isoforms
(DSC1–3); DSC2 is almost ubiquitous in human tissues,
but it is the only desmocollin isoform expressed in cardiac
tissue [22].
DSC2 is a membrane glycoprotein composed of four
highly conserved extracellular subdomains (EC1–4), a
more variable extracellular anchor domain (EA), a single
transmembrane domain (TM), an intracellular anchor
domain (IA) and a cytoplasmic region that can show two
different isoforms.
Cadherins are synthesized as inactive precursor proteins
containing a prosequence followed by the cadherin
domains. The N-terminal prosequence is proteolytically
cleaved off in the late Golgi and the mature cadherin is
then transported to the plasma membrane. Proteolytic
removal of the prosequence results in structural rearrange-
ments within EC1 domain with the activation of adhesive
properties [23]. Mutation p.E102K alters a conserved
amino acid located in the propeptide region.
Mutation p.I345T is located in the EC2 domain, which
forms, together with EC1, the "minimal essential unit" to
mediate cell adhesion, through cis and trans interactions
among desmosomal cadherins [24].
In vitro functional studies on neonatal rat cardiomyocytes
and on HL-1 cells demonstrate that the two missense
mutations in the N-terminal domain affect the normal
localisation of DSC2. As previously reported, the wild-
type DSC2a-GFP fusion protein was efficiently incorpo-
rated into desmosomes and did not exert dominant-nega-
tive effect when overexpressed [25]. A lower amount of
GFP signal was detected in the cytoplasm, since proteins
were still not fully trafficked to the membrane. Unlike
wild-type DSC2, the N-terminal mutants were predomi-
nantly located in the cytoplasm. Further investigation will
be needed to determine whether the mutations could
induce "null alleles" potentially leading to haploinsuffi-
ciency (i.e. through cytoplasmic degradation) or the
mutant proteins could be present in the tissue and act in
a dominant fashion (i.e. gain-of-function).
While the involvement of genes encoding desmosomal
proteins in ARVC suggests that disruption of desmosomal
integrity might be among primary molecular defects [8],
pathogenetic mechanisms leading to ARVC remain to be
elucidated. Recent data from Garcia-Gras et al. on cardiac
restricted dsp-deficient mice would point at a novel molec-
ular mechanism through suppression of Wnt/β-catenin
signaling by nuclear plakoglobin [26].
DSC2 mutations were detected in two ARVC probands
and in four family members who met only minor diag-
nostic criteria. This is consistent with incomplete pene-
trance of the disease, as previously reported in ARVC
patients family members carrying DSP, PKP2 and DSG2
mutations [7,27-29]. However, due to the young age of
most of the family members carrying the DSC2 muta-
tions, we cannot exclude that some of them could later
show clinical signs of the disease.
None of the probands carrying the pathogenic mutations
showed gross skin/hair abnormalities. All DSC isoforms
are expressed in the epidermal tissues, whereas DSC2 is
the only one expressed in the myocardium. We may
hypothesize that compensation by other DSC isoforms
might take place in the epidermis but not in the myocar-
dium of DSC2 mutation carriers, thus accounting for the
cardiac-specific phenotype.
Conclusion
In conclusion, we identified two novel missense muta-
tions in DSC2 gene associated with ARVC. In vitro func-
tional test demonstrated that N-terminal mutated DSC2 is
almost exclusively distributed throughout the cytoplasm,
thus suggesting the potential pathogenic effect of the
reported mutations.
Identification of additional DSC2 mutations associated
with ARVC may result in early detection of asymptomatic
carriers and in increased diagnostic accuracy in the clinical
evaluation of family members.
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